Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.24.18_SUPPL.3003PMID 27955060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting mTORC1 to promote ferroptosis and apoptosis in endometrial cancer with PI3K-Akt-mTOR pathway mutation

  2025cites this paper
• Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature

  2022cites this paper
• Advanced and recurrent endometrial cancer: state of the art and future perspectives.

  2022cites this paper
• Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma

  2021influential citation
• Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

  2020cites this paper
• Targeted Therapy and Prevention of Endometrial Cancer

  2017cites this paper
• Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas

  2015cites this paper
• Past, Present and Future Perspectives on the Management of Endometrial Cancer— A Comprehensive Review

  2015cites this paper
• Targeted therapy in gynecologic cancers: Ready for prime time?

  2015cites this paper
• Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer

  2014cites this paper
• Endometrial cancer: molecular and therapeutic aspects.

  2013cites this paper
• New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)

  2013cites this paper
• Current status of molecular-targeted drugs for endometrial cancer (Review)

  2013cites this paper
• Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

  2013cites this paper
• Treatment of Advanced Stage and Recurrent Endometrial Cancer in Elderly Women

  2013cites this paper
• Updates in therapy for uterine serous carcinoma

  2013cites this paper
• HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

  2013cites this paper
• The 13th European Cancer Conference (ECCO 13)

  2012cites this paper
• Targeted therapy for high-risk endometrial carcinoma

  2012cites this paper
• Traitement systémique du cancer de l’endomètre avancé

  2012cites this paper
• Endometrial cancer.

  2012cites this paper
• [Systemic therapy for advanced endometrial cancer].

  2012cites this paper
• Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

  2012cites this paper
• Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

  2012cites this paper
• A phase I study of temsirolimus and metformin in advanced solid tumours

  2012cites this paper
• Contemporary management of endometrial cancer.

  2012cites this paper
• Mammalian Target of Rapamycin (mTOR) Inhibitors

  2011cites this paper
• Recent advances in systemic therapy for advanced endometrial cancer

  2011cites this paper
• Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.

  2011cites this paper
• Targeted Therapeutics in Cancer Treatment

  2011cites this paper
• Targeting the mTOR/4E-BP Pathway in Endometrial Cancer

  2011cites this paper
• Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?

  2011cites this paper
• Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2011cites this paper
• The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.

  2011cites this paper
• Developments in the systemic treatment of endometrial cancer.

  2011cites this paper
• Early clinical cancer trials: Proof of concept and beyond

  2011cites this paper
• Unresolved issues in the management of endometrial cancer

  2011cites this paper
• Adjuvant Treatment of Advanced-stage Endometrial Cancer

  2011cites this paper
• Cancer de l’endomètre

  2011cites this paper
• A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

  2011cites this paper
• Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

  2011cites this paper
• Recurrent Endometrial Cancer

  2011cites this paper
• Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

  2011cites this paper
• Novel therapies in gynaecological cancer

  2011cites this paper
• mTOR signaling and drug development in cancer

  2010cites this paper
• Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy

  2010cites this paper
• Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?

  2010cites this paper
• Promising novel therapies for the treatment of endometrial cancer.

  2010cites this paper
• Molecular Characteristics and Risk Factors in Endometrial Cancer: What Are the Treatment and Preventative Strategies?

  2010cites this paper
• Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

  2010cites this paper
• Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).

  2010cites this paper
• Emerging drugs in endometrial cancers

  2010cites this paper
• Treatment for advanced and recurrent endometrial carcinoma: combined modalities.

  2010cites this paper
• A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

  2010cites this paper
• Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report.

  2010cites this paper
• Controversies in the Management of Endometrial Cancer

  2010cites this paper
• Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.

  2010cites this paper
• Chemistry and Pharmacology of Rapamycin and Its Derivatives

  2010cites this paper
• A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

  2010cites this paper
• Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy

  2010cites this paper
• mTOR and Cancer Therapy: Clinical Development and Novel Prospects

  2009cites this paper
• Recent advances in the treatment of advanced or recurrent endometrial cancer

  2009cites this paper
• The role of mTOR in the management of solid tumors: an overview.

  2009cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

  2009cites this paper
• mTOR and Cancer Therapy: General Principles

  2009cites this paper
• Targeting mtor-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses

  2009cites this paper
• [Targeted therapies and their indications in solid neoplasias].

  2009cites this paper
• Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

  2009cites this paper
• Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

  2009cites this paper
• Current treatment of metastatic endometrial cancer.

  2009cites this paper
• Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.

  2009cites this paper
• Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

  2009cites this paper
• Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways

  2008cites this paper
• mTOR Inhibitors in Oncology

  2008cites this paper
• Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC

  2008cites this paper
• mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

  2008cites this paper
• New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.

  2008cites this paper
• A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

  2008cites this paper
• Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.

  2008cites this paper
• NCCN Task Force Report: mTOR inhibition in solid tumors.

  2008cites this paper
• Molecule-targeted agents in endometrial cancer

  2008cites this paper
• Molecular target therapies in endometrial cancer: From the basic research to the clinic

  2008cites this paper
• Mammalian target of rapamycin as a therapeutic target in oncology

  2008cites this paper
• mTOR inhibitors in the treatment of cancer

  2008cites this paper
• Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.

  2007cites this paper
• The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy

  2007cites this paper
• Targeted mTOR in Human Gynecologic Cancers

  2007cites this paper
• Targeting the mTOR signaling network in cancer.

  2007cites this paper
• Molecular Targeted Therapies in the Treatment of Ovarian Cancer

  2007cites this paper
• Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development

  2007cites this paper
• TOR (target of rapamycin) as an anti-cancer target

  2007cites this paper
• Current Status of Signal Transduction Modulators in the Treatment of Gynecologic Malignancies

  2007cites this paper
• Systemic therapy in metastatic or recurrent endometrial cancer.

  2007cites this paper
• Investigating mammalian target of rapamycin inhibitors for their anticancer properties

  2006cites this paper
• Abstracts

  2005cites this paper